We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

ELITechGroup

Offers a range of products for in vitro diagnostics in clinical chemistry, hemostasis, microbiology, immunology, and ... read more Featured Products: More products

Download Mobile App





ELITech Group Distributes More Than 3.5 Million COVID-19 Tests and Installs Over 500 PCR Systems Globally

By LabMedica International staff writers
Posted on 19 Aug 2020
ELITechGroup Molecular Diagnostics (Puteaux, France) has distributed more than 3.5 million SARS-CoV-2 tests and also installed more than 500 ELITe InGenius polymerase chain reaction (PCR) systems, globally, with over a 100 systems placed since the start of the COVID-19 pandemic.

ELITechGroup has been at the forefront of fighting the COVID-19 outbreak in Europe and has been supplying tests on its ELITe InGenius system since early March in Italy, and other affected countries, such as France, the UK, the Benelux and more. More...
The ELITe InGenius system has been widely used in hospitals and other healthcare settings since 2016, and thanks to its reliability and easy adaptability, ELITechGroup was among the first companies to have SARS-CoV-2 tests on a sample-to-result system. The ELITe InGenius system allows laboratories to reliably detect SARS-CoV-2 in only a few hours, as well as conducting parallel testing for other diseases, such as flu, in order to ensure a correct diagnosis. The fully automated solution can process 12 samples in parallel to deliver results in less than 2.5 hours. This brings several benefits over centralized high-throughput testing approaches as there is no waiting for a large batch of samples to accumulate before testing, and no delays from sending samples off premises to a central laboratory.

By performing extraction, amplification and result interpretation in one device, the ELITe InGenius replaces the multiple devices needed to perform such tasks separately. Full automation also means there is no need for constant supervision, allowing laboratory staff to perform other valuable work. More importantly, the limited hands-on time helps reduce the risk of infection for users. The instrument is straightforward to use, with only minimal training from ELITechGroup's service and support team required. The ELITe InGenius offers the widest molecular diagnostics menu available on a sample-to-result system, with 38 CE-IVD assays dedicated to the individual needs of healthcare settings, be it immuno-compromised patient monitoring; detection of respiratory, gastro-intestinal, sexually transmitted or nosocomial infections; meningitis and encephalitis, as well as diagnostics of genetic factors.

"The continued rapid spread of the novel coronavirus makes it important for every country to test as many patients as possible, as quickly as possible," said ELITechGroup CEO, Christoph Gauer. "We are proud to have played an essential role in equipping healthcare staff with the testing tools they need. We have now expanded our manufacturing capacity to help provide additional ELITe InGenius systems to both new and existing hospitals and laboratories, globally and to support healthcare systems to prepare for the expectedly increasing demand for rapid and reliable diagnostics for all patients."


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.